Trial Profile
F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (IND 123119, Protocol D
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Jan 2024
Price :
$35
*
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Diagnostic use
- Acronyms AV ADAD; DIAN
- 29 Jun 2021 Study design is changed from open, interventional to masked roles unspecified and observational. Phase is changed from phase 2 to not specified.
- 29 Jun 2021 Status changed from active, no longer recruiting to recruiting.
- 16 Mar 2021 Planned End Date changed from 1 Sep 2021 to 1 Sep 2024.